- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Prenetics Global Limited: Prenetics Launches IM8 Daily Ultimate Essentials PRO - A Clinical Formula with Two New Flavours | 1 | GlobeNewswire (USA) | ||
| 18.02. | Prenetics veräußert Insighta-Beteiligung für 70 Millionen US-Dollar an Tencent | 15 | Investing.com Deutsch | ||
| 18.02. | Prenetics Global Limited: Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR in 12 Months, Revenue Surges 480% YoY | 547 | GlobeNewswire (Europe) | Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 millionIM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR MilestoneStrategic... ► Artikel lesen | |
| PRENETICS GLOBAL Aktie jetzt für 0€ handeln | |||||
| 17.02. | Prenetics appoints longevity expert Dr. Darshan Shah to board | 3 | Investing.com | ||
| 17.02. | Prenetics Global Limited: Prenetics Appoints Renowned Longevity Expert and Health-Tech CEO, Dr. Darshan Shah, to Board of Directors | 687 | GlobeNewswire (Europe) | Appointment Strengthens Board with Deep Clinical and Commercial Expertise in Healthspan Optimization, Aligning with IM8 Growth Strategy NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Prenetics Global... ► Artikel lesen | |
| 17.02. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.02. | Prenetics Global Limited: Prenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity | 829 | GlobeNewswire (Europe) | Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt Q4 and Full-Year 2025 Financial Results to be Announced Pre-Market on February 18, 2026... ► Artikel lesen | |
| 15.02. | Quant snapshot: IAMGOLD, Prenetics lead strong buys as Sol Strategies, Endava lag | 18 | Seeking Alpha | ||
| 13.02. | Prenetics Global Limited: Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder | 1 | GlobeNewswire (USA) | ||
| 11.02. | Roth/MKM initiates Prenetics stock with Buy rating on IM8 supplement success | 1 | Investing.com | ||
| 11.02. | Roth/MKM stuft Prenetics mit "Buy" ein - Erfolg von IM8-Nahrungsergänzungsmittel als Treiber | 2 | Investing.com Deutsch | ||
| 06.01. | Prenetics divests 3PL distribution business in all-stock deal valued at up to $13M | 2 | Seeking Alpha | ||
| 05.01. | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.12.25 | David Beckham's Prenetics halts $1B Bitcoin plan to focus on IM8 health brand | 1 | iNVEZZ.com | ||
| 30.12.25 | Prenetics halts Bitcoin purchases to focus on consumer health brand, IM8 | 2 | Seeking Alpha | ||
| 30.12.25 | Prenetics Global Limited: Prenetics Announces Update to Capital Allocation Strategy; Ceases Bitcoin Purchases to Focus on IM8 | 266 | GlobeNewswire (Europe) | Company's Capital and Strategic Focus Now Exclusively Focused on IM8 IM8 FY 2026 Revenue Projected to Reach $180 - $200 Million CHARLOTTE, N.C., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Prenetics Global... ► Artikel lesen | |
| 23.12.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.12.25 | Prenetics Global Limited: Prenetics Enters Into Warrant Exchange Agreements With Warrant Holders, Strengthening Capital Structure | 334 | GlobeNewswire (Europe) | CHARLOTTE, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and... ► Artikel lesen | |
| 11.12.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.11.25 | Prenetics executives purchase $1.4 million in company stock | 1 | Investing.com |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 162,45 | +0,06 % | WONBIOGEN Co., Ltd: Won BioGen Accelerates Global Market Expansion with Advanced Moist Wound Care Technology | SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Medical device manufacturer Won BioGen (CEO Kim Won-il) is accelerating its global market expansion based on its advanced moist wound care... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 661,60 | 0,00 % | Regeneron und Sanofi erhalten Empfehlung für erweiterte Dupixent-Zulassung | DJ Regeneron und Sanofi erhalten Empfehlung für erweiterte Dupixent-Zulassung
Von Colin Kellaher
DOW JONES--Der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,340 | -1,19 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| TEMPUS AI | 45,000 | -0,44 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| ABIVAX | 101,80 | -0,97 % | EQS-News: ABIVAX: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 | EQS-News: ABIVAX
/ Key word(s): Study results
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory... ► Artikel lesen | |
| XOMA ROYALTY | 22,200 | +1,83 % | Leerink raises Xoma stock price target on royalty outlook | ||
| CANSINO BIOLOGICS | 3,786 | +7,13 % | CanSino Biologics Inc: CanSinoBIO's Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential | HONG KONG, Feb 24, 2026 - (ACN Newswire) - CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by... ► Artikel lesen | |
| SINO BIOPHARM | 0,633 | -1,52 % | Aktienmarkt: Aktie von Sino Biopharmaceutical tritt auf der Stelle (0,88 €) | Wenig Kursbewegung zur Stunde bei der Sino Biopharmaceutical-Aktie . Das Wertpapier notiert aktuell bei 0,88 Euro. Ein geringes Minus von 5,12 Prozent zeigt die Kurstafel für die Aktie von Sino Biopharmaceutical... ► Artikel lesen | |
| GUARDANT HEALTH | 79,62 | +0,15 % | Guardant Health buys Israeli co MetaSight Diagnostics | ||
| AC IMMUNE | 2,490 | +0,40 % | AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor | ||
| AGENUS | 2,780 | -1,42 % | Agenus Inc.: Agenus meldet Abschluss einer strategischen Kooperationsvereinbarung mit Zydus Lifesciences im Wert von 141 Millionen US-Dollar zur Weiterentwicklung von BOT+BAL und Stärkung der Produktionskapazitäten in den USA | Agenus Inc. (Nasdaq: AGEN), ein führendes Unternehmen auf dem Gebiet der Immunonkologie, gab heute den Abschluss seiner bereits angekündigten strategischen Zusammenarbeit mit Zydus Lifesciences... ► Artikel lesen | |
| ARDELYX | 5,422 | -1,99 % | Hedge Fund and Insider Trading News: Paul Singer, David Tepper, Warren Buffett, Bill Ackman, Caxton Associates, Bridgewater Associates, Hycroft Mining Holding Corporation (HYMC), Ardelyx Inc (ARDX), and More | ||
| ALKERMES | 26,800 | +4,69 % | Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 | Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,500 | -1,32 % | Johnson Fistel, PLLP: Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses | San Diego, California--(Newsfile Corp. - February 19, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 116,00 | +0,87 % | Palvella Therapeutics Inc.: Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations | Primary endpoint met with statistically significant improvement (mean change of +2.13; p Achieved statistical significance on pre-specified key secondary endpoint (p 95% of trial participants aged... ► Artikel lesen |
Das Unternehmen PRENETICS GLOBAL LIMITED kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,900 (-5,06 %) liegt der Kurs bei 16,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRENETICS GLOBAL LIMITED finden Sie auf Wallstreet Online.